DEVELOPMENT OF PRODRUG APPROACHES FOR LONG-ACTING NANOFORMULATIONS OF EMTRICITABINE-BASED REGIMENS
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 1F31AI129549-01A1; Amer Al-Khouja; 05/01/17 - 04/30/19
NIH/NIAID: 5R01AI120748-02; Marc Michael Baum (PI); 06/26/15 - 05/31/20
NIH/NIAID: 1R01AI131416-01; Andrew Martin Bellinger (PI); 03/22/17 - 02/28/22
NIH/NIAID: 4R01AI073146-09; Victor J. Garcia-Martinez (PI); 01/05/02 - 07/31/17
NIH/NIAID: 5R01AI117740-03; Christopher J. Destache (PI); 02/04/16 - 01/31/18
NIH/NIAD; 1R01AI131430-01; Soumya Rahima Benhabbour (PI); 03/06/17 - 02/29/20
In this application, researchers propose to utilize novel synthetic chemistry to develop a series of aliphatic tenofovir prodrugs designed to greatly enhance cellular uptake and to provide prolonged intracellular exposure to molecules with potent antiviral activity. They will further extend systemic exposure to these compounds by delivering them in slow-release nanoparticle formulations. They believe that with this “dual-modulation” of drug presentation we will provide systemic exposure to therapeutic concentrations of highly active antiviral compounds for periods of at least four weeks following intramuscular injection.
NIH/NIMH; 5R01MH106380-02; Sarit A. Golub (PI); 01/16/15 - 11/30/19
NIH/NIAID; 4R01AI073146-09: Victor J. Garcia-Martinez (PI); 05/01/07 - 07/31/17
NIH/NIAID; 5UM1AI120184-02; Thomas Hope (PI); 07/07/15 - 06/30/20